Merck's KEYTRUDA Gains European Approval for Two New Gynecologic Cancer Treatments MD Bureau25 Oct 2024 5:47 PM ISTWith these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement.
Merck discontinues Phase 3 trial of Xevinapant in locally advanced head and neck cancer Ruchika Sharma27 Jun 2024 5:04 PM ISTGermany: Merck, a science and technology company, has announced the discontinuation of the Phase III randomized TrilynX study evaluating...
Merck gets USFDA nod for Keytruda plus chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical Cancer Ruchika Sharma13 Jan 2024 1:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Preoperative FOLFOX as good as chemoradiotherapy for increasing survival in locally advanced rectal cancer Dr. Shravani Dali15 Sept 2023 9:00 AM ISTPreoperative FOLFOX is as good as chemoradiotherapy for increasing survival in locally advanced rectal cancer suggests a new study published in the...
Chemoradiotherapy may be safely omitted in some patients with locally advanced rectal cancer: PROSPECT trial Medha Baranwal11 Jun 2023 8:00 PM ISTUSA: Findings from the PROSPECT trial have shown preoperative FOLFOX to be non-inferior to preoperative chemoradiotherapy for disease-free survival...
FAPI-PET predicts concurrent chemoradiotherapy response in esophageal cancer patients: Study Medha Baranwal31 Oct 2022 8:00 PM ISTChina: Positron emission tomography (PET) imaging with a fibroblast activation protein inhibitor (FAPI) radiotracer may predict if esophageal cancer...
Intensity-modulated radiation therapy alone effective in low-risk nasopharyngeal carcinoma: JAMA Dr. Shravani Dali30 Aug 2022 7:30 PM ISTAmong patients with low-risk nasopharyngeal carcinoma, intensity-modulated radiation therapy (IMRT) alone compared with concurrent chemoradiotherapy...
Sugemalimab: safe and effective consolidation therapy for patients with unresectable Stage III NSCLC Dr. Kamal Kant Kohli10 Aug 2022 8:00 PM ISTThe human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung...
Immunotherapy may play role in treating nonmetastatic gastroesophageal cancer Dr. Kamal Kant Kohli17 May 2022 7:45 PM ISTROCHESTER, Minn: Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these...
